p53 Activation in Platinum-Resistant High Grade Serous Ovarian Cancer, a Study of PLD With APR-246
Status:
Completed
Trial end date:
2019-07-10
Target enrollment:
Participant gender:
Summary
The purpose of this study is to make a preliminary assessment of the efficacy of a combined
APR-246 and PLD chemotherapy regimen in patients with platinum-resistant recurrent high grade
serous ovarian cancer (HGSOC) with mutated TP53. In addition, the study aims to assess the
safety profile of the combined APR-246 and PLD chemotherapy regimen, to evaluate potential
biomarkers, and to assess the biological activity in tumor and surrogate tissues. The trial
will enroll at least 25 evaluable patients.